Tcipatent Report 2016 Weeks 21-24
Reports comprise records taken from the Online Database. Report Types:-
4-Weekly Reports published every 4 weeks showing the latest records added to the database – text-searchable PDFs, published since 1 January 2014. Back issues available.
Bespoke Reports from the Database using selected criteria, e.g. by Drug, Patentee etc. (contact us for prices)
Sample report contents:
Axitinib, Bepridil, Canagliflozin, Carfilzomib, Caspofungin, Ceftolozane, Ceftolozane, Ceftolozane, Ceftolozane, Cytarabine, Daclatasvir, Docetaxel, Esomeprazole, Gadobutrol, Gemcitabine, Glycopyrronium bromide, Lansoprazole, Ledipasvir, Lurasidone, Metyrapone, Olmutinib, Ospemifene, Ospemifene, Pantoprazole, Rabeprazole, Regorafenib, Sapropterin, Sitagliptin, Sofosbuvir
Reports comprise records taken from the Online Database. Report Types:-
4-Weekly Reports published every 4 weeks showing the latest records added to the database – text-searchable PDFs, published since 1 January 2014. Back issues available.
Bespoke Reports from the Database using selected criteria, e.g. by Drug, Patentee etc. (contact us for prices)
Sample report contents:
Axitinib, Bepridil, Canagliflozin, Carfilzomib, Caspofungin, Ceftolozane, Ceftolozane, Ceftolozane, Ceftolozane, Cytarabine, Daclatasvir, Docetaxel, Esomeprazole, Gadobutrol, Gemcitabine, Glycopyrronium bromide, Lansoprazole, Ledipasvir, Lurasidone, Metyrapone, Olmutinib, Ospemifene, Ospemifene, Pantoprazole, Rabeprazole, Regorafenib, Sapropterin, Sitagliptin, Sofosbuvir
Marketed Drug Process Patent Report [Extracted from the Claimed Intermediate Structure Searchable Database] Weeks 21 - 24/2016 (23 May - 19 June 2016) © The Claimed Intermediate • www.tcipatent.com
- Page 2: This Claimed Intermediate Report is
- Page 5 and 6: Contents: Weeks 21 - 24/2016 (23 Ma
- Page 7 and 8: New process patents for named, mark
- Page 9 and 10: New process patents for named, mark
- Page 11 and 12: New process patents for named, mark
- Page 13 and 14: New process patents for named, mark
- Page 15 and 16: New process patents for named, mark
- Page 17 and 18: New process patents for named, mark
- Page 19 and 20: New process patents for named, mark
- Page 21 and 22: New process patents for named, mark
- Page 23 and 24: New process patents for named, mark
- Page 25 and 26: New process patents for named, mark
- Page 27 and 28: New process patents for named, mark
- Page 29 and 30: New process patents for named, mark
- Page 31 and 32: New process patents for named, mark
- Page 33 and 34: New process patents for named, mark
- Page 35 and 36: New process patents for named, mark
- Page 37: For a subscription to the Text/Stru
Marketed Drug Process Patent <strong>Report</strong><br />
[Extracted from the Claimed Intermediate Structure Searchable Database]<br />
<strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
© The Claimed Intermediate • www.tcipatent.com
This Claimed Intermediate <strong>Report</strong> is compiled from The<br />
Claimed Intermediate Database entries.<br />
The <strong>Report</strong>s cover new DE, EP, FR, GB, US and WO patent<br />
specifications concerned with Process Patents for named<br />
Marketed Pharmaceutical Drugs and published as a Four-<br />
Weekly <strong>Report</strong>. Earlier Process Patents for named Marketed<br />
Pharmaceutical Drugs will be included on an ongoing basis for<br />
specific drugs in a Drug Process Patent History <strong>Report</strong>. The<br />
Claimed Intermediate Database of Pharmaceutical Process<br />
Patents for Marketed Pharmaceutical Drugs provides up-todate<br />
comprehensive data for such specific drugs.<br />
Due to the number of languages encountered in patent<br />
specifications, it is not always possible to provide an entry.<br />
However, these will be included in The Claimed<br />
Intermediate Database of Pharmaceutical Process Patents<br />
for Marketed Pharmaceutical Drugs when an inhouse<br />
readable language patent family equivalent emerges (eg a<br />
published EP patent specification).<br />
Only new patent specifications, i.e. first equivalent<br />
specification published (exclusions above), will be included<br />
in the <strong>Report</strong>s and Database. This is to avoid multiple<br />
equivalent ‘family’ specifications being reported. Such<br />
equivalent ‘family’ specifications may be identified via free<br />
or commercial patent equivalent databases.<br />
With regard to the Drug Process Patent History <strong>Report</strong>,<br />
the drugs will be selected inhouse. However, requests for<br />
specific drugs will be welcomed and included under<br />
appropriate anonymity to protect commercial interests.<br />
Structures visible to 300+ zoom.<br />
Accuracy is paramount in identifying such Process Patents and<br />
everything is done to provide a full and complete report.<br />
However, due in particular to the vagaries of various Patent<br />
Classification systems, it may not always be possible to give<br />
such full and complete reports. Where omissions or errors<br />
have been made these would not have been done intentionally<br />
and checks will be made from time to time to review the patent<br />
documents inspected and where such omissions or errors are<br />
noted or pointed out these will be included in The Claimed<br />
Intermediate Database of Pharmaceutical Process Patents for<br />
Marketed Pharmaceutical Drugs which will be amended<br />
accordingly. Usual publishing terms and conditions apply.<br />
© The Claimed Intermediate • www.tcipatent.com
Contents: <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Page<br />
1<br />
2<br />
3<br />
4<br />
5<br />
6<br />
7<br />
8<br />
9<br />
10<br />
11<br />
12<br />
13<br />
14<br />
15<br />
16<br />
17<br />
18<br />
19<br />
20<br />
<strong>21</strong><br />
22<br />
Drug Name<br />
Anagliptin<br />
Buprenorphine<br />
Canagliflozin<br />
Ceritinib<br />
Daclatasvir<br />
Darunavir<br />
Efinaconazole<br />
Emtricitabine<br />
Ibrutinib<br />
Idelalisib<br />
Ivabradine<br />
Ledipasvir<br />
Luliconazole<br />
Micafungin ( Anidulafungin )<br />
Miglustat<br />
Obeticholic acid<br />
Palbociclib<br />
Palbociclib<br />
Praziquantel<br />
Revaprazan<br />
Sertraline<br />
Tafluprost ( Lubiprostone )<br />
Patentee<br />
Suzhou Jonathan New Material Technology Co., Ltd.<br />
Siegfried AG<br />
Cipla Limited<br />
Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.<br />
Sun Pharmaceutical Industries Limited<br />
Lupin Limited<br />
Mapi Pharma Ltd.<br />
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<br />
Sun Pharmaceutical Industries Limited<br />
Ratiopharm GmbH<br />
Richter Gedeon NYRT.<br />
Shanghai Forefront Pharmaceutical., Ltd.<br />
Glenmark Pharmaceuticals Limited<br />
DSM Sinochem Pharmaceuticals Netherlands B.V.<br />
Navinta LLC et al<br />
Dextra Laboratories Limited<br />
Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Merck Patent GmbH<br />
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.<br />
Council of Scientific & Industrial Research<br />
Apotex Inc.
Contents: <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Page<br />
23<br />
<strong>24</strong><br />
25<br />
26<br />
27<br />
28<br />
29<br />
30<br />
31<br />
Drug Name<br />
Tedizolid phosphate<br />
Telmisartan<br />
Teneligliptin<br />
Trazodone<br />
Treprostinil<br />
Vemurafenib<br />
Vildagliptin<br />
Vortioxetine<br />
Vortioxetine<br />
Patentee<br />
Sun Pharmaceutical Industries Limited<br />
Virginia Commonwealth University<br />
Sun Pharmaceutical Industries Limited<br />
Suzhou Jonathan New Material Technology Co., Ltd.<br />
Everlight Chemical Industrial Corporation<br />
Shilpa Medicare Limited<br />
Suzhou Jonathan New Material Technology Co., Ltd.<br />
Dipharma Francis S.r.l<br />
Megafine Pharma (P) Ltd.
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Anagliptin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078109<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10663657<br />
Patentee: Suzhou Jonathan New Material Technology Co., Ltd.<br />
Patent Description: Anagliptin appears to be obtained via the prepared intermediate (2S)-N-chloroacetyl-2-cyanopyrrolidine. Vildagliptin also appears to be prepared.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 1
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Buprenorphine<br />
Patent Specification<br />
Number: EP 3023427<br />
Publication Date:<br />
<strong>2016</strong>-05-25<br />
First Filing<br />
Priority Details: 20141119EP193857<br />
Patentee: Siegfried AG<br />
Patent Description: Buprenorphine is obtained from oripavine via N-alkylation, 7-acetylation, 7-hydroxyalkylation and etheno reduction.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 2
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Canagliflozin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/083790<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141125IN3731<br />
Patentee: Cipla Limited<br />
Patent Description: Canagliflozin is obtained via prepared claimed intermediate IIIc.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 3
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ceritinib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/081538<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141118US62/081119<br />
Patentee: Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.<br />
Patent Description: Ceritinib is obtained via the N-arylation reaction as shown. X-ray defined ceritinib crystalline Form Beta is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 4
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Daclatasvir<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079697<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119IN3344/DEL<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Daclatasvir is obtained via the preparation of intermediate II.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 5
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Darunavir<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/092525<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>2IN3990/MUM<br />
Patentee: Lupin Limited<br />
Patent Description: Darunavir is obtained by hydrogenating nitro-darunavir.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 6
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Efinaconazole<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079728<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141123US62/083233<br />
Patentee: Mapi Pharma Ltd.<br />
Patent Description: Efinaconazole is obtained via prepared claimed intermediates 3 and 4 and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 7
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Emtricitabine<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078584<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141118CN10660872<br />
Patentee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<br />
Patent Description: Emtricitabine is obtained purified by separating out emtricitabine benzoate from an aqueous solution.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 8
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ibrutinib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079693<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119IN3343/DEL<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Ibrutinib is obtained via claimed intermediates VI and VIII and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 9
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Idelalisib<br />
Patent Specification<br />
Number: EP 3031808<br />
Publication Date:<br />
<strong>2016</strong>-06-15<br />
First Filing<br />
Priority Details: 20141209EP196931<br />
Patentee: Ratiopharm GmbH<br />
Patent Description: Idelalisib is obtained as hydrochloride salt via N-deprotection and crystallisation with hydrochloric acid. X-ray defined idelalisib hydrochloride salt is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 10
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ivabradine<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079684<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119HU545<br />
Patentee: Richter Gedeon NYRT.<br />
Patent Description: Ivabradine is obtained via prepared intermediate II from 3,4-dimethoxyphenylacetic acid (III).<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 11
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Ledipasvir<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078505<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141120CN10668957<br />
Patentee: Shanghai Forefront Pharmaceutical., Ltd.<br />
Patent Description: Ledipasvir is obtained via the preparation of a fluorene ethyl ketone which is fluorinated with eg N-fluorobenzenesulfonimide (NFSI).<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 12
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Luliconazole<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/09<strong>24</strong>78<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>2IN3992/MUM<br />
Patentee: Glenmark Pharmaceuticals Limited<br />
Patent Description: Luliconazole is obtained as shown and purified via preparation of an acid addition salt. X-ray defined luliconazole hydrochloride is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 13
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Micafungin ( Anidulafungin )<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/091746<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>1EP197387<br />
Patentee: DSM Sinochem Pharmaceuticals Netherlands B.V.<br />
Patent Description: Micafungin is obtained via the acylation of FR 179642 with prepared claimed intermediate (2). The preparation of anidulafungin is referred to.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 14
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Miglustat<br />
Patent Specification<br />
Number: EP 3031800<br />
Publication Date:<br />
<strong>2016</strong>-06-15<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>1US62/90783<br />
Patentee: Navinta LLC et al<br />
Patent Description: Miglustat is obtained with high purity without the use of a flash column chromatography or ion exchange.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 15
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Obeticholic acid<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079517 + WO <strong>2016</strong>/079518 + W<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119GB20593 + 20141119GB20594<br />
Patentee: Dextra Laboratories Limited<br />
Patent Description: Obeticholic acid is obtained via the dioxo reduction of claimed intermediate (I) and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 16
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Palbociclib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/082605<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141126CN106930911<br />
Patentee: Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Patent Description: Palbociclib is obtained via ring-closing, substitution, condensation and hydrolysis reactions.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 17
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Palbociclib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/082604<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141126CN106912330<br />
Patentee: Suzhou Miracpharma Technology Co., Ltd and Zheren Pharmaceutical Nanjing Co., Ltd<br />
Patent Description: Palbociclib is obtained via ring-closing, substitution, condensation and dehydrogenation reaction steps.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 18
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Praziquantel<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078765<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 201411<strong>21</strong>EP3933<br />
Patentee: Merck Patent GmbH<br />
Patent Description: (R)-Praziquantel is obtained via (R)-praziquanamine obtained from a salt of (R)-praziquanacetamide with a >/=14C chiral 2-arylpropionic acid, eg (S)-naproxen.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 19
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Revaprazan<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078542<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10665839<br />
Patentee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.<br />
Patent Description: Revaprazan is obtained via cyclisation, chlorination and N-arylation.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 20
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Sertraline<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/088138<br />
Publication Date:<br />
<strong>2016</strong>-06-09<br />
First Filing<br />
Priority Details: 20141201IN3482/DEL<br />
Patentee: Council of Scientific & Industrial Research<br />
Patent Description: Sertraline is obtained via prepared claimed intermediates Ia and Ib and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page <strong>21</strong>
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Tafluprost ( Lubiprostone )<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/090461<br />
Publication Date:<br />
<strong>2016</strong>-06-16<br />
First Filing<br />
Priority Details: 20141<strong>21</strong>0US62/090035<br />
Patentee: Apotex Inc.<br />
Patent Description: Tafluprost is obtained via claimed crystalline 1-adamantanamine intermediate 6a. Other process intermediates are claimed. The preparation of lubiprostone is referred to.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 22
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Tedizolid phosphate<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/088103<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Tedizolid phosphate is obtained as shown.<br />
Publication Date:<br />
<strong>2016</strong>-06-09<br />
First Filing<br />
Priority Details: 20141205IN3548/DEL<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 23
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Telmisartan<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/089845<br />
Publication Date:<br />
<strong>2016</strong>-06-09<br />
First Filing<br />
Priority Details: 20141201US62/085842<br />
Patentee: Virginia Commonwealth University<br />
Patent Description: Telmisartan is obtained via a Suzuki cross-coupling reaction between the prepared trifluoroborate intermediate and 2-bromo-1-methylbenzimidazole.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page <strong>24</strong>
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Teneligliptin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079699<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119IN3342/DEL<br />
Patentee: Sun Pharmaceutical Industries Limited<br />
Patent Description: Tenelegliptin is obtained via the aqueous phase preparation of (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-L-proline - intermediate IV.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 25
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Trazodone<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078107<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10663127<br />
Patentee: Suzhou Jonathan New Material Technology Co., Ltd.<br />
Patent Description: Trazodone is obtained via the preparation of the intermediate 1-(3-chlorophenyl)-4-(3-chloropropane)piperazine.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 26
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Treprostinil<br />
Patent Specification<br />
Number: US <strong>2016</strong>/0152548<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141201TW103141569<br />
Patentee: Everlight Chemical Industrial Corporation<br />
Patent Description: Treprostinil is obtained via claimed intermediates (II) and (VIII-I) and analogues as defined.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 27
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vemurafenib<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/083956<br />
Publication Date:<br />
<strong>2016</strong>-06-02<br />
First Filing<br />
Priority Details: 20141129IN5990/CHE<br />
Patentee: Shilpa Medicare Limited<br />
Patent Description: Vemurafenib is obtained and purified via a trifluoromethane sulfonic acid salt.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 28
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vildagliptin<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/078109<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141119CN10663657<br />
Patentee: Suzhou Jonathan New Material Technology Co., Ltd.<br />
Patent Description: Vildagliptin appears to be obtained via the prepared intermediate (2S)-N-chloroacetyl-2-cyanopyrrolidine. Anagliptin also appears to be prepared.<br />
Significant Step:<br />
Claimed Comment: Not Clear<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 29
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vortioxetine<br />
Patent Specification<br />
Number: EP 3023417<br />
Publication Date:<br />
<strong>2016</strong>-05-25<br />
First Filing<br />
Priority Details: 201411<strong>21</strong>ITMI142018<br />
Patentee: Dipharma Francis S.r.l<br />
Patent Description: Vortioxetine is obtained via claimed intermediate IV. Other intermediates are claimed.<br />
Significant Step:<br />
Claimed Comment: Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 30
New process patents for named, marketed, pharmaceutical drugs<br />
published <strong>Weeks</strong> <strong>21</strong> - <strong>24</strong>/<strong>2016</strong> (23 May - 19 June <strong>2016</strong>)<br />
Drug Name: Vortioxetine<br />
Patent Specification<br />
Number: WO <strong>2016</strong>/079751<br />
Publication Date:<br />
<strong>2016</strong>-05-26<br />
First Filing<br />
Priority Details: 20141117IN3612/MUM<br />
Patentee: Megafine Pharma (P) Ltd.<br />
Patent Description: Vortioxetine is obtained via the reaction of prepared 2-[(2,4-dimethylphenyl)thio]aniline with a dialkyl amine compound. X-ray defined crystalline vortioxetine<br />
hydrobromide Form M1 is claimed.<br />
Significant Step:<br />
Claimed Comment: None Claimed<br />
Claimed<br />
Intermediate:<br />
Basic Patent Status: Application Stage<br />
Page 31
For a subscription to the Text/Structure searchable Database visit the Website or contact 'info' as below<br />
www.tcipatent.com<br />
info@tcipatent.com<br />
T: +44 (0) 1273 736 080<br />
© <strong>Tcipatent</strong> Ltd • www.tcipatent.com
Change language